Literature DB >> 1545963

Neuralgia-inducing cavitational osteonecrosis (NICO). Osteomyelitis in 224 jawbone samples from patients with facial neuralgia.

J E Bouquot1, A M Roberts, P Person, J Christian.   

Abstract

A somewhat obscure etiologic theory for facial neuralgias presumes a low-grade osteomyelitis of the jaws that produces neural degeneration with subsequent production of inappropriate pain signals. Animal investigations and treatment successes with human patients based on this theory lend it credence. The present study examined 224 tissue samples removed from alveolar bone cavities in 135 patients with trigeminal neuralgia or atypical facial neuralgia. All tissue samples demonstrated clear evidence of chronic intraosseous inflammation. The most common microscopic features included dense marrow fibrosis or "scar" formation, a sprinkling of lymphocytes in a relative absence of other inflammatory cells (especially histiocytes), and smudged, nonresorbing necrotic bone flakes. Very little healing or new bone formation was visible. These lesions were able to burrow several centimeters to initiate distant cavities. The present preliminary investigation cannot prove etiology, but the presence of intraosseous inflammation in every single jawbone specimen in these patients and certain clinical and treatment aspects of these lesions (to be reported later) has led the authors to recommend the term neuralgia-inducing cavitational osteonecrosis or NICO for these lesions.

Entities:  

Mesh:

Year:  1992        PMID: 1545963     DOI: 10.1016/0030-4220(92)90127-c

Source DB:  PubMed          Journal:  Oral Surg Oral Med Oral Pathol        ISSN: 0030-4220


  13 in total

1.  Bisphosphonate-associated mandibular osteonecrosis.

Authors:  E Carneiro; P Vibhute; A Montazem; P M Som
Journal:  AJNR Am J Neuroradiol       Date:  2006-05       Impact factor: 3.825

2.  Single-nucleotide polymorphisms of the SLC17A9 and P2RY12 genes are significantly associated with phantom tooth pain.

Authors:  Moe Soeda; Seii Ohka; Daisuke Nishizawa; Junko Hasegawa; Kyoko Nakayama; Yuko Ebata; Ken-Ichi Fukuda; Kazutaka Ikeda
Journal:  Mol Pain       Date:  2022 Jan-Dec       Impact factor: 3.395

3.  Chemokine RANTES/CCL5 as an unknown link between wound healing in the jawbone and systemic disease: is prediction and tailored treatments in the horizon?

Authors:  Johann Lechner; Volker von Baehr
Journal:  EPMA J       Date:  2015-05-06       Impact factor: 6.543

4.  Peripheral Neuropathic Facial/Trigeminal Pain and RANTES/CCL5 in Jawbone Cavitation.

Authors:  Johann Lechner; Volker von Baehr
Journal:  Evid Based Complement Alternat Med       Date:  2015-06-11       Impact factor: 2.629

5.  Osteoporosis in the jawbones: a correlative factor of primary trigeminal neuralgia?

Authors:  Li Liu; Hu Wang; Na Liu; Qianmei Yang; En Luo
Journal:  Med Sci Monit       Date:  2014-08-20

6.  Aseptic-avascular osteonecrosis: local "silent inflammation" in the jawbone and RANTES/CCL5 overexpression.

Authors:  Johann Lechner; Sabine Schuett; Volker von Baehr
Journal:  Clin Cosmet Investig Dent       Date:  2017-11-09

7.  RANTES and fibroblast growth factor 2 in jawbone cavitations: triggers for systemic disease?

Authors:  Johann Lechner; Volker von Baehr
Journal:  Int J Gen Med       Date:  2013-04-22

8.  Hyperactivated Signaling Pathways of Chemokine RANTES/CCL5 in Osteopathies of Jawbone in Breast Cancer Patients-Case Report and Research.

Authors:  Johann Lechner; Volker von Baehr
Journal:  Breast Cancer (Auckl)       Date:  2014-05-21

9.  Treatments' outcomes of patients suffered from trigeminal neuralgia in kerman, iran.

Authors:  Javad Faryabi; Maryam Joolhar
Journal:  J Dent (Shiraz)       Date:  2014-09

10.  Immunohistological staining of unknown chemokine RANTES/CCL5 expression in jawbone marrow defects-osteoimmunology and disruption of bone remodeling in clinical case studies targeting on predictive preventive personalized medicine.

Authors:  Johann Lechner; Tilman Schulz; Volker von Baehr
Journal:  EPMA J       Date:  2019-08-06       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.